SCHEMBL2035494

SCHEMBL2035494

O=C(O)C(=CNc1ccccc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 1/20 0.47
NFKB1 P19838 1/20 0.47
RAB9A P51151 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TP53 P04637 2/20 0.44
EPHX1 P07099 1/20 0.44
TSHR P16473 1/20 0.44
EPHX2 P34913 1/20 0.44
CDK9 P50750 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
DHODH Q02127 2/20 0.44
PKM P14618 1/20 0.42
TGM2 P21980 1/20 0.42
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12495123 0.85 ALDH1A1 (0.47) ALDH1A1MAPTKDM4ESMN1; SMN2NPC1
SCHEMBL12495120 0.85 ALDH1A1 (0.47) ALDH1A1MAPTKDM4ESMN1; SMN2NPC1
SCHEMBL14222603 0.85 DHODH (0.41) ALDH1A1MAPTKDM4ESMN1; SMN2NPC1
SCHEMBL4516541 0.83 NAPRT (0.54) ALDH1A1MAPTKDM4ESMN1; SMN2NPC1
SCHEMBL25191564 0.81 MAPT (0.47) ALDH1A1MAPTKDM4ERAB9ANPSR1
SCHEMBL19329260 0.81 MAOA (0.46) ALDH1A1MAPTSMN1; SMN2NPC1NFKB1
SCHEMBL4272031 0.81 DHODH (0.41) ALDH1A1NPSR1EPHX1EPHX2DHODH
SCHEMBL11022963 0.81 NPC1 (0.44) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL30824201 0.81 MDM2 (0.47) ALDH1A1KDM4ESMN1; SMN2DHODHNAPRT
SCHEMBL1733300 0.79 SMN1; SMN2 (0.61) ALDH1A1MAPTKDM4ESMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0684942-B1 METHOD FOR PREPARING QUINOLINE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF HOECHST CELANESE CORP (US) 1998-06-10 EP claimed
EP-0684942-A4 1995-12-27 EP claimed
EP-0684942-A1 METHOD FOR PREPARING QUINOLINE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF HOECHST CELANESE CORPORATION (US) 1995-12-06 EP claimed
US-5430152-A Heating aminoarylester in presence of chlorosulfonic acid, oleum HOECHST CELANESE CORPORATION (US) 1995-07-04 US claimed
WO-1994019312-A1 METHOD FOR PREPARING QUINOLINE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF HOECHST CELANESE CORPORATION (US) 1994-09-01 WO claimed
US-4079058-A Process of performing cyclization reactions using benzyl or pyridylamino malonic acid derivatives DYNAMIT NOBEL AG (DT) 1978-03-14 US claimed
JP-11158150-A None JP disclosed
US-10894773-B2 Deuterated CFTR potentiators VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) 2021-01-19 US disclosed
US-20200290971-A1 DEUTERATED CFTR POTENTIATORS VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) 2020-09-17 US disclosed
US-10479766-B2 Deuterated CFTR potentiators Verex Pharmaceuticals (Europe) Limited (GB) 2019-11-19 US disclosed
EP-3538512-A1 NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES Bayer Animal Health GmbH (DE) 2019-09-18 EP disclosed
EP-3235812-B1 DEUTERATED DERIVATIVES OF IVACAFTOR VERTEX PHARMACEUTICALS EUROPE LTD (GB) 2019-09-04 EP disclosed
US-20190169129-A1 DEUTERATED CFTR POTENTIATORS VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) 2019-06-06 US disclosed
US-4390541-A ANTIALLERGENS; ANTISPASMODIC AGENTS LILLY INDUSTRIES LIMITED (GB) 1983-06-28 US disclosed
EP-0055068-A1 Quinolone derivatives and their use as pharmaceuticals Lilly Industries Limited (GB) 1982-06-30 EP disclosed
EP-0022078-A1 Pyrazolo-quinolines, processes for their production, and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1981-01-07 EP disclosed
US-4079058-A Process of performing cyclization reactions using benzyl or pyridylamino malonic acid derivatives DYNAMIT NOBEL AG (DT) 1978-03-14 US disclosed
US-4079058-A Process of performing cyclization reactions using benzyl or pyridylamino malonic acid derivatives DYNAMIT NOBEL AG (DT) 1978-03-14 US disclosed
US-3981717-A ANILINO COMPOUNDS AMERICAN CYANAMID COMPANY (US) 1976-09-21 US disclosed
US-3907798-A Preparation of 4H-pyrido{8 1,2-a{9 pyrimidin-4-ones from cyclic alkylidene 2-pyridylaminomethylenemalonates STERLING DRUG INC 1975-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190169129-A1 DEUTERATED CFTR POTENTIATORS CFTR, SLC26A3, SLC26A4 ALDH1A1 1205/4885MAPT 4868/4885KDM4E 4762/4885
US-20200290971-A1 DEUTERATED CFTR POTENTIATORS CFTR, SLC26A3, SLC26A4 ALDH1A1 1205/4885MAPT 4868/4885KDM4E 4762/4885
US-10479766-B2 Deuterated CFTR potentiators CFTR, SLC26A3, SLC26A4 ALDH1A1 1205/4885MAPT 4868/4885KDM4E 4762/4885
US-10894773-B2 Deuterated CFTR potentiators CFTR, SLC26A3, SLC26A4 ALDH1A1 1205/4885MAPT 4868/4885KDM4E 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.